國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Clinical pharmacokinetic and pharmac...

Ensom, Mary H.H.

Clinical pharmacokinetic and pharmacodynamic drug interactions associated with antimalarials

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Clinical pharmacokinetic and pharmacodynamic drug interactions associated with antimalarialsby Tony K.L. Kiang, Kyle John Wilby, Mary H.H. Ensom.
作者:	Kiang, Tony K.L.
其他作者:	Wilby, Kyle John.
出版者:	Cham :Springer International Publishing :2015.
面頁冊數:	vii, 146 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
標題:	AntimalarialsPharmacokinetics.
電子資源:	http://dx.doi.org/10.1007/978-3-319-10527-7
ISBN:	9783319105277 (electronic bk.)

Clinical pharmacokinetic and pharmacodynamic drug interactions associated with antimalarials
Kiang, Tony K.L.

Clinical pharmacokinetic and pharmacodynamic drug interactions associated with antimalarials[electronic resource] /by Tony K.L. Kiang, Kyle John Wilby, Mary H.H. Ensom. - Cham :Springer International Publishing :2015. - vii, 146 p. :ill., digital ;24 cm.

Introduction -- Pharmacology of Recommended Antimalarial Agents -- Drug Interaction Potential of Antimalarial Drugs Based on Known Metabolic Properties of Antimalarials -- Pharmacokinetic Drug Interactions Affecting Antimalarials -- Effects of Antimalarials on the Pharmacokinetics of Co-Administered Drugs -- Effects of Antimalarials on the Pharmacokinetics of Co-Administered Antimalarials -- Pharmacodynamic Interactions: Clinical Evidence for Combination Therapy, In Vitro Interactions, and In Vivo Interactions -- Limitations, Future Directions, and Conclusions.

This comprehensive review provides a systematic, unbiased analysis, critique and summary of the available literature and generates novel clinical decision-making algorithms which can aid clinicians and scientists in practice management and research development. Potential mechanisms for the identified drug interactions are deduced from available preclinical and in vitro data which are interpreted in the context of the in vivo findings. Current limitations and gaps in the literature are summarized, and potential future research directions / experimentations are also suggested. In addition to the main objective to review the available clinical pharmacokinetic and pharmacodynamic drug interactions associated with WHO-recommended antimalarial drugs on the market today (i.e. chloroquine, amodiaquine, sulfadoxine, pyrimethamine, mefloquine, artemisinin, artemether, artesunate, dihydroartemisinin, artemotil, lumefantrine, primaquine, atovaquone, proguanil, piperaquine and quinine), this book also provides succinct chapter summaries on the epidemiology of malaria infection, diagnosis and therapeutics, in vivo pharmacology and chemistry, preclinical pharmacology, in vitro pharmacodynamics, in vitro reaction phenotyping, and in vitro drug-drug interaction data associated with the identified antimalarial drugs.

ISBN: 9783319105277 (electronic bk.)

Standard No.: 10.1007/978-3-319-10527-7doiSubjects--Topical Terms:

712541
Antimalarials
--Pharmacokinetics.

LC Class. No.: RC159.A5

Dewey Class. No.: 616.9362061

Clinical pharmacokinetic and pharmacodynamic drug interactions associated with antimalarials
LDR:02881nmm a2200313 a 4500 001 460834
003 DE-He213
005 20150724100116.0
006 m d
007 cr nn 008maaau
008 151110s2015 gw s 0 eng d
020 $a 9783319105277 (electronic bk.)
020 $a 9783319105260 (paper)
024 7 $a 10.1007/978-3-319-10527-7 $2 doi
035 $a 978-3-319-10527-7
040 $a GP $c GP
041 0 $a eng
050 4 $a RC159.A5
072 7 $a MMRT $2 bicssc
072 7 $a MED097000 $2 bisacsh
082 0 4 $a 616.9362061 $2 23
090 $a RC159.A5 $b K46 2015
100 1 $a Kiang, Tony K.L. $3 712538
245 1 0 $a Clinical pharmacokinetic and pharmacodynamic drug interactions associated with antimalarials $h [electronic resource] / $c by Tony K.L. Kiang, Kyle John Wilby, Mary H.H. Ensom.
260 $a Cham : $b Springer International Publishing : $b Imprint: Adis, $c 2015.
300 $a vii, 146 p. : $b ill., digital ; $c 24 cm.
505 0 $a Introduction -- Pharmacology of Recommended Antimalarial Agents -- Drug Interaction Potential of Antimalarial Drugs Based on Known Metabolic Properties of Antimalarials -- Pharmacokinetic Drug Interactions Affecting Antimalarials -- Effects of Antimalarials on the Pharmacokinetics of Co-Administered Drugs -- Effects of Antimalarials on the Pharmacokinetics of Co-Administered Antimalarials -- Pharmacodynamic Interactions: Clinical Evidence for Combination Therapy, In Vitro Interactions, and In Vivo Interactions -- Limitations, Future Directions, and Conclusions.
520 $a This comprehensive review provides a systematic, unbiased analysis, critique and summary of the available literature and generates novel clinical decision-making algorithms which can aid clinicians and scientists in practice management and research development. Potential mechanisms for the identified drug interactions are deduced from available preclinical and in vitro data which are interpreted in the context of the in vivo findings. Current limitations and gaps in the literature are summarized, and potential future research directions / experimentations are also suggested. In addition to the main objective to review the available clinical pharmacokinetic and pharmacodynamic drug interactions associated with WHO-recommended antimalarial drugs on the market today (i.e. chloroquine, amodiaquine, sulfadoxine, pyrimethamine, mefloquine, artemisinin, artemether, artesunate, dihydroartemisinin, artemotil, lumefantrine, primaquine, atovaquone, proguanil, piperaquine and quinine), this book also provides succinct chapter summaries on the epidemiology of malaria infection, diagnosis and therapeutics, in vivo pharmacology and chemistry, preclinical pharmacology, in vitro pharmacodynamics, in vitro reaction phenotyping, and in vitro drug-drug interaction data associated with the identified antimalarial drugs.
650 0 $a Antimalarials $x Pharmacokinetics. $3 712541
650 0 $a Antimalarials $x Receptors $x Effect of drugs on. $3 712542
650 1 4 $a Medicine & Public Health. $3 273799
650 2 4 $a Tropical Medicine. $3 274942
650 2 4 $a Health Promotion and Disease Prevention. $3 274213
650 2 4 $a Drug Safety and Pharmacovigilance. $3 701740
700 1 $a Wilby, Kyle John. $3 712539
700 1 $a Ensom, Mary H.H. $3 712540
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-10527-7
950 $a Medicine (Springer-11650)